Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SQZ Biotechnologies
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
January 18, 2023
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
November 30, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
November 10, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
November 09, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
August 04, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
July 11, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
June 01, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
May 31, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
May 18, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
May 10, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
May 05, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
May 05, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at Upcoming Investor Conferences
May 03, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
April 27, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
April 11, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at Upcoming Investor Conferences
April 06, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes
April 04, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease
March 21, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates
March 16, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation
February 01, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
January 24, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor
January 06, 2022
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 29, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
November 12, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate Into Combination With Checkpoint Inhibitors
October 26, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
October 04, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference
September 30, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at Cantor Global Healthcare Conference
September 27, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform
September 13, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
SQZ Biotechnologies to Present at Upcoming Health Care Conferences
September 09, 2021
From
SQZ Biotechnologies
Via
Business Wire
Tickers
SQZ
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.